Browsing Tag
GenSight Biologics
2 posts
Can early access to GS010 in Israel accelerate GenSight’s push toward full regulatory approval?
GenSight Biologics secures Israeli early access for GS010 gene therapy in LHON. Find out how this could reshape access, manufacturing, and investor outlook.
GenSight Biologics completes LUMEVOQ tech transfer to Catalent to enable global clinical expansion
GenSight Biologics advances gene therapy LUMEVOQ® through strategic manufacturing transfer to Catalent, bolstering regulatory readiness and clinical scale-up.